DrugPatentWatch Database Preview
Drugs in Development Information for Bavituximab
Development status for investigational drug Bavituximab: Sponsors, patents, clinical trial progress
Bavituximab is an investigational drug.
There have been 25 clinical trials for Bavituximab.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2013.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Breast Neoplasms. The leading clinical trial sponsors are Peregrine Pharmaceuticals, University of Texas Southwestern Medical Center, and Merck Sharp & Dohme Corp.
There are twenty-eight US patents protecting this investigational drug and seven hundred and thirty-nine international patents.
Summary for Bavituximab
| US Patents | 28 |
| International Patents | 739 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2013-12-01) |
| Vendors | 0 |
Recent Clinical Trials for Bavituximab
| Title | Sponsor | Phase |
|---|---|---|
| An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients | Merck Sharp & Dohme Corp. | Phase 2 |
| An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients | Oncologie Inc. | Phase 2 |
| Randomized Phase II Study of Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide Progression | Genzyme, a Sanofi Company | Phase 2 |
Clinical Trial Summary for Bavituximab
Top disease conditions for Bavituximab
Top clinical trial sponsors for Bavituximab
US Patents for Bavituximab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Bavituximab | See Pricing | Multispecific constructs | AbbVie Stemcentrx LLC (North Chicago, IL) | See Pricing |
| Bavituximab | See Pricing | .beta.-glucan methods and compositions that affect the tumor microenvironment | BIOTHERA, INC. (Eagan, MN) | See Pricing |
| Bavituximab | See Pricing | Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein | CureVac AG (Tubingen, DE) | See Pricing |
| Bavituximab | See Pricing | Method of treating pancreatic cancer | ChemoCentryx, Inc. (Mountain View, CA) | See Pricing |
| Bavituximab | See Pricing | Compositions and methods for detecting protease activity in biological systems | CytomX Therapeutics, Inc. (South San Francisco, CA) | See Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Bavituximab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Bavituximab | Canada | 2900764 | 2033-02-08 | See Pricing |
| Bavituximab | European Patent Office | 2954056 | 2033-02-08 | See Pricing |
| Bavituximab | Hong Kong | 1218930 | 2033-02-08 | See Pricing |
| Bavituximab | Japan | 2016509014 | 2033-02-08 | See Pricing |
| Bavituximab | World Intellectual Property Organization (WIPO) | 2014124326 | 2033-02-08 | See Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
